Series C+ · 2026-10-19 · Healthcare
Nouscom raises $135.0M
78
AI Score
Amount
$135.0M
Round
Series C+
Lead
M Ventures, Revelation Partners
HQ
CH
Why it matters: The round shows what a registration-enabling prevention trial costs in Europe, and the story is candid that the Phase 1b/2 data had no control group.
Nouscom raised a $135M Series D co-led by M Ventures and Revelation Partners to fund a global registration-enabling trial of NOUS-209.
- Participants:
- Angelini Industries, Angelini Investments, European Investment Bank, Aurea, Angelini Ventures, Neva SGR, Intesa Sanpaolo Group, 5AM Ventures, Andera Partners, EQT Life Sciences, Indaco Venture Partners, Panakes Partners
- Source:
- Tech Funding News ↗ · Midu summary
Other rounds by Nouscom
Deal Dossier PRO
Pro feature
Deal Dossier for Nouscom
Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.
Generate dossier — ProFigures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).
Recent Healthcare rounds
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing